Novel olanzapine analogues presenting a reduced H 1 receptor affinity and retained 5HT 2A/D 2 binding affinity ratio

BMC Pharmacology

Volumn 12, Issue , 2012, Pages

  Jafari, Somayeh ^a   Bouillon, Marc E ^a   Huang, Xu Feng ^a,b   Pyne, Stephen G ^a   Fernandez Enright, Francesca ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

5HT 2A D 2 affinity ratio; H1 receptors; Novel antipsychotics; Olanzapine

Indexed keywords

AMOXAPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; LOXAPINE; OLANZAPINE; SEROTONIN 2A RECEPTOR;

ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY;

EID: 84862564982     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-12-8     Document Type: Article

References (51)

1. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. Synthese 2005, 172:1703-1711.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologist Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologist.
3. Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005, 20:15-27. 10.1016/j.eurpsy.2004.11.003, 15642439.
4. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000, 57:238-255.
5. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719. 10.1038/261717a0, 945467.
6. Serretti A, Ronchi DD, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 2004, 11:343-358. 10.2174/0929867043456043, 14965236.
7. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008, 68:2269-2292. 10.2165/0003495-200868160-00002, 18973393.
8. Conley RR, Kelly DL. Second generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. J Psychiatry Relat Sci 2005, 42:51-60.
9. Oakley NR, Hayes AG, Sheehan MJ. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology 1991, 105:204-208. 10.1007/BF02244310, 1686655.
10. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002, 14:123-129.
11. Zhang Y, Xu H, He J, Yan B, Jiang W, Li X. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment. Neurosci Lett 2007, 420:66-71. 10.1016/j.neulet.2007.04.007, 17466452.
12. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997, 58:55-62.
13. Meltzer HY, Matsubara S, Lee JC. The ratios of seretonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
14. Tehan BG, Lioyd EJ, Wong MG. Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. J Mol Graph Model 2001, 19:418-426.
15. Buckley P. Olanzapine: a critical review of recent literature. Expert Opin Pharmacother 2005, 6:2077-2089. 10.1517/14656566.6.12.2077, 16197360.
16. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
17. Breden EL, Liu MT, Dean SR. Metabolic and cardiacs side effects of second-generation antipsychotics: what every clinician should known. J Pharm Pract 2009, 22:478-488.
18. Holt RI. Severe mental illness, antipsychotic drugs and the metabolic syndrome. The BJDVD 2006, 6:199-204.
19. Jones B, Basson BR, Walker DJ, Crawford MK, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001, 62:41-44. 10.4088/JCP.v62n0109, 11495096.
20. Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subject. Biol Psychiatry 2009, 65:607-613. 10.1016/j.biopsych.2008.10.037, 19103435.
21. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004, 14:115-119. 10.1016/S0924-977X(03)00072-5, 15013026.
22. Bai YM, Chen TT, Yang WS, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8. 10.1016/j.schres.2009.03.014, 19409756.
23. Reynolds GP, Zhang Z, Zhang X. Association of antipsychotic drug induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359:2086-2087. 10.1016/S0140-6736(02)08913-4, 12086765.
24. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Bryan L, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003, 28:519-526.
25. Mathews M, Muzina JD. Atypical antipsychotics: new drugs, new challenges. Clevel Clin J Med 2007, 74:597-606.
26. Reynolds GP, Kirk SL. Metabolic side effect of antipsychotic treatment-pharmacological mechanism. Pharmacol Ther 2010, 125:169-179. 10.1016/j.pharmthera.2009.10.010, 19931306.
27. Coccurello R, Moles A. Potential mechanism of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010, 127:210-251. 10.1016/j.pharmthera.2010.04.008, 20493213.
28. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology 2009, 207:119-125. 10.1007/s00213-009-1639-8, 19688201.
29. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008, 60:582-589. 10.1016/j.neuron.2008.09.033, 2631191, 19038216.
30. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JW, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. B J Pshych 2008, 192:424-428.
31. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200. 10.1097/01213011-200504000-00002, 15864111.
32. Clifton PG, Rusk IN, Cooper SJ. Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci 1991, 105:272-281.
33. Benaliouad F, Kapur S, Rompre PP. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007, 32:551-561. 10.1038/sj.npp.1301136, 16794561.
34. Matsui-Sakate A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of contribution of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005, 20:368-378. 10.2133/dmpk.20.368, 16272755.
35. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. PNAS 2007, 104:3456-3459. 10.1073/pnas.0611417104, 1805549, 17360666.
36. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53:2250-2260. 10.2337/diabetes.53.9.2250, 15331534.
37. Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci 2006, 27:279-284. 10.1016/j.tips.2006.03.008, 16584790.
38. Mercer LP. Histamine and the neuroregulation of food intake. Nutrition 1997, 13:581-582. 10.1016/S0899-9007(97)00028-2, 9263246.
39. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Bryan L, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526. 10.1038/sj.npp.1300027, 12629531.
40. Mercer LP, Kelley DS, Haq AU, Humphries LL. Dietary induced anorexia: a review of involvement of the histaminergic system. J Am Coll Nutr 1996, 15:223-230.
41. Pijl H, Meinders AE. Body weight change and adverse effect of drug treatment. Echansm and management. Drug Saf 1996, 14:329-342. 10.2165/00002018-199614050-00005, 8800628.
42. Recasens C. Body weight changes and psychotropic drug treatment: neuroleptics. Encephale 2001, 27:269-276.
43. Jafari S, Fernandez-Enright F, Huang X-F. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem 2012, 120:371-384. 10.1111/j.1471-4159.2011.07590.x, 22103329.
44. Chakrabarti JK, Horsman L, Hotten TM, Pullar IA, Tupper DE, Wright FC. 4-piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics. J Med Chem 1980, 23:878-884. 10.1021/jm00182a013, 6105216.
45. Shastri JA, Bhatnagar A, Thaper RK, Dubey SK. Process for Producing Pure Form of 2-Methyl-4-(4-Methyl-1-Piperazinyl)-10H-Thiono[2,3-b][1,5]Benzodiazepine U.S. Patent 2006, WO 2006006180 A1 20060119.
46. Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, et al. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J Med Chem 2004, 47:143-157. 10.1021/jm0309811, 14695828.
47. Durand M, Aguerre S, Fernandez F, Edno L, Combourieu I, Mormède P, Chaouloff F. Strain-dependent neurochemical and neuroendocrine effects of desipramine, but not fluoxetine or imipramine, in spontaneously hypertensive and Wistar-Kyoto rats. Neuropharmacology 2000, 39:2464-2477. 10.1016/S0028-3908(00)00088-5, 10974331.
48. Campiani G, Butini S, Fattorusso C, Trotta F, Gemma S, Catalanotti B, Nacci V, Fiorini I, Cagnotto A, Mereghetti I, et al. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J Med Chem 2005, 48:1705-1708. 10.1021/jm049629t, 15771414.
49. Seeman P. Dopamine D2 receptors as treatment target in schizophrenia. Clin Schizophr Relat Psychoses 2010, 4:56-73. 10.3371/CSRP.4.1.5, 20643630.
50. Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108. 10.1016/0006-2952(73)90196-2, 4202581.
51. Bradford MM. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.